抗血管生成药物在非小细胞肺癌中的应用及研究进展

Application and Research Progress of Anti-angiogenic Drugs in Non-small Cell Lung Cancer

新生血管的形成是肿瘤生长、进展、转移的基础,此过程涉及各类受体介导的细胞信号通路,其中刺激血管生成作用最强的生长因子是血管内皮生长因子(VEGF)。随着VEGF作用的深入认识和血管靶向治疗的临床实践,以抗新生血管为核心的治疗策略取得显著成效。现将抗血管药物的作用机制及其在治疗非小细胞肺癌中的研究进展作简要综述。

The formation of new blood vessels is the basis of tumor growth,progression,and metastasis.This process involves various receptor-mediated cellular signaling pathways.The growth factor that stimulates angiogenesis is vascular endothelial growth factor(VEGF).With the deep understanding of the role of VEGF and the clinical practice of vascular targeted therapy,the treatment strategy against the neovascularization has achieved remarkable results.The mechanism of action of anti-angiogenic drugs and its research progress in the treatment of non-small cell lung cancer are briefly reviewed.